<DOC>
	<DOC>NCT01066065</DOC>
	<brief_summary>The advent of new antiretroviral drugs improved the management of HIV naive patients in terms of efficacy. However, the long term metabolic profile of this drugs has not yet been compared and associations between new antiretrovirals and cardiovascular events remains controversial. Moreover, the better tolerability and easy dosage of this new drugs might hypothetically influence adherence and QOL of HIV patients.</brief_summary>
	<brief_title>Metabolic Safety of Raltegravir Versus Darunavir in HIV Naive Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>VIH1 pregnancy previous Antiretroviral exposure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>cardiovascular disease</keyword>
	<keyword>HIV</keyword>
	<keyword>metabolic disorder</keyword>
	<keyword>HIV naive patients initiating HAART with Raltegravir or boosted Darunavir</keyword>
</DOC>